All In Biotech

Drug Trial Radar · NCT05050084

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,050 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,050

Planned (sponsor's estimate)

Start

Dec 6, 2021

Primary completion

Nov 11, 2026

Study completion Nov 11, 2031

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.

Conditions

  • Prostate Adenocarcinoma

Interventions

  • BicalutamideDrug

    Drug

  • BuserelinDrug

    Drug

  • DarolutamideDrug

    Given PO

  • DegarelixDrug

    Drug

  • FlutamideDrug

    Drug

  • GoserelinDrug

    Drug

  • HistrelinDrug

    Drug

  • LeuprolideDrug

    Drug

  • Radiation TherapyRadiation

    Undergo RT

  • RelugolixDrug

    Drug

  • TriptorelinDrug

    Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distant metastasis (DM) (De-intensification study)Time frame: From randomization to the detection of distant metastasis by conventional imaging, assessed up to 5 years
  2. Metastasis-free survival (MFS) (Intensification study)Time frame: From randomization until the occurrence of distant metastasis by conventional imaging or death from any cause, assessed up to 5 years

Locations

576 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Arizona Center for Cancer Care - Gilbert

    Gilbert, Arizona

  • Arizona Center for Cancer Care-Peoria

    Peoria, Arizona

  • Arizona Center for Cancer Care - Phoenix

    Phoenix, Arizona

  • Arizona Center for Cancer Care - Scottsdale

    Scottsdale, Arizona

  • Arizona Center for Cancer Care-Surprise

    Surprise, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • City of Hope Corona

    Corona, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente Dublin

    Dublin, California

  • UC San Diego Health System - Encinitas

    Encinitas, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Washington Hospital

    Fremont, California

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Marin General Hospital

    Greenbrae, California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • City of Hope Antelope Valley

    Lancaster, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente- Modesto MOB II

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Providence Queen of The Valley

    Napa, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Kaiser Permanente Downtown Commons

    Sacramento, California

Showing 40 of 576 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.